Learn More
AIMS To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD). METHODS Six hundred twenty-nine subjects with CVD who smoked >/=10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150 mg twice daily) or(More)
BACKGROUND Bupropion sustained release (bupropion SR) has been shown to increase smoking cessation success rates in the US studies. OBJECTIVE To determine whether bupropion SR, in combination with counselling, is effective for smoking cessation in a multi-country study. METHODS This randomized, double-blind, placebo-controlled trial enrolled 707(More)
OBJECTIVE To evaluate bupropion SR for smoking cessation in physicians and nurses. METHODS This double-blind prospective 26-center, 12-country trial randomized 687 subjects to smoking cessation counselling with bupropion SR or placebo for 7 weeks. The participants were followed for 52 weeks. RESULTS Bupropion SR was superior to placebo (50% vs 40%,(More)
In this international, multicentre, double-blind, placebo-controlled, single attack study, 'triptan naive' migraine patients were randomized in an 8:8:1 ratio to receive zolmitriptan 5 mg, sumatriptan 100 mg or placebo. The all-treated analysis included 1058 patients who took study medication. The primary endpoint, complete headache response, was reported(More)